Before visiting, please review our current visitor policies and COVID-19 information.
ECOG-ACRIN EA2182
Trial Overview
Official Title
Study Lower-Dose Chemoradiation for Early-Stage Anal Cancer
Study Purpose
To compare lower-dose chemoradiation therapy to standard-dose chemoradiation therapy and to find out if this approach is better or worse than the usual approach for anal cancer.
Diagnosis
Anal CancerEligibility
Patients can be HIV-positive or HIV-negative.
Patients must have no history of prior radiation or chemotherapy for this malignancy.
Patients must not have had a potentially curative surgery for this cancer prior to enrolling in this study.
Patients must sign an approved informed consent and authorization permitting release of personal health information.
Intervention
- Study Treatment: Chemoradiation, which is when you receive both chemotherapy and radiation
- Group 1: Standard dose of chemoradiation therapy
- Group 2: Lower dose of chemoradiation therapy
- Quality of Life questionnaires
- Patients must keep a pill diary.
After completion of chemoradiation therapy, patients will be followed for up to 5 years and watch for side effects, monitor cancer, and complete questionnaires.
For more information, visit ClincialTrials.gov